Drug intelligence / Profile preview

GSM-779690T

Development stage: Phase 1
Lead developer: Acta Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

GSM-779690T is an investigational oral small molecule drug being developed to modulate levels of specific amyloid beta (Aβ) peptide isoforms in adults. Currently, it is in first-in-human clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, with a particular focus on its effects on amyloid beta-related pathways, which are implicated in Alzheimer's disease[1][3][5][7].

Targets

GSEC (Gamma-Secretase Complex)

Beyond the preview

Go deeper on GSM-779690T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSM-779690T.

Explore the full profile